| Lucy Burchill, | |
|
2820 Mount Rushmore Rd, Rapid City, SD 57701-5462 | |
| (605) 342-3280 | |
| Not Available |
| Full Name | Lucy Burchill |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 2820 Mount Rushmore Rd, Rapid City, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780637488 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 0248 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lucy Burchill, 2820 Mount Rushmore Rd, Rapid City, SD 57701-5462 Ph: () - | Lucy Burchill, 2820 Mount Rushmore Rd, Rapid City, SD 57701-5462 Ph: (605) 342-3280 |
News Archive
Cambridge Cognition today announced a series of new contracts for its cloud-based CANTAB Connect software platform for the Human Abuse Liability (HAL) testing of investigational drugs.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.
Researchers led by Dr. Soheil Dadras at the Stanford University Medical Center have developed a novel methodology to extract microRNAs from cancer tissues. The related report by Ma et al, "Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens," appears in the September 2009 issue of the Journal of Molecular Diagnostics.
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has launched the first large-scale, multicenter study to investigate the effectiveness of body cooling treatment in infants and children who have had cardiac arrest. The Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) trials total more than $21 million over six years.
Early detection of lung disease in cystic fibrosis (CF), combined with aggressive treatment in infants, may be the key to controlling the progression of the disease, according to a recent study.
› Verified 1 days ago
Maria Sargent, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-755-1000 | |
Kayla Sayer, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 640 Flormann St, Rapid City, SD 57701 Phone: 605-755-3300 | |
Jennifer Ann Erdman, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 636 Saint Anne St, Rapid City, SD 57701 Phone: 605-348-8000 Fax: 605-348-4315 | |
Natasha Gray, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2805 5th St, Rapid City, SD 57701 Phone: 605-755-5700 | |
Morgan Folchert, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1760 Centre St Ste 2, Rapid City, SD 57703 Phone: 308-249-2912 | |
Paulette A Kirby, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 811 Columbus St, Rapid City, SD 57701 Phone: 605-343-3007 | |
Rebecca Bierle, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4150 5th St, Rapid City, SD 57701 Phone: 605-755-4300 |